IMM — ImmuPharma Cashflow Statement
0.000.00%
Last trade - 00:00- £63.34m
- £62.95m
Annual cashflow statement for ImmuPharma, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.59 | -6.59 | -3.03 | -3.06 | -2.48 |
| Depreciation | |||||
| Non-Cash Items | 1.43 | 0.619 | 0.115 | 0.235 | 0.308 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.656 | 1.02 | 0.449 | 1.43 | 0.343 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -3.33 | -4.83 | -2.35 | -1.36 | -1.77 |
| Capital Expenditures | -0.36 | -0.051 | -0.106 | 0 | -0.002 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.209 | 0.001 | 0.029 | 0.189 | 1.3 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.569 | -0.05 | -0.077 | 0.189 | 1.29 |
| Financing Cash Flow Items | -0.945 | -2.12 | -0.803 | -0.759 | 0.5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 8.37 | 0.702 | 1.55 | 0.722 | 0.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.5 | -4.21 | -0.982 | -0.459 | 0.028 |